ARCT - Arcturus Therapeutics Holdings Inc.
| Previous Close | 10.90 |
| Open | 11.07 |
| Bid | 6.35 x 900 |
| Ask | 11.34 x 1000 |
| Day's Range | 10.46 - 11.07 |
| 52 Week Range | 4.11 - 15.50 |
| Volume | 64,962 |
| Avg. Volume | 88,314 |
| Market Cap | 142.995M |
| Beta (3Y Monthly) | 3.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
- Zacks
What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock
Arcturus Therapeutics (ARCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- Zacks
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 86.79% and 153.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Can European Expansion Aid Canopy Growth (CGC) Q1 Earnings?
Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.
- Zacks
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?
Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.
- Zacks
5 High-Flying Stocks Set to Beat on Earnings in Q2 Next Week
In line with better-than-expected earnings reports, five companies are set to beat earnings estimates next week.
- Zacks
Arcturus Therapeutics (ARCT) Expected to Beat Earnings Estimates: Should You Buy?
Arcturus Therapeutics (ARCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2
Ultragenyx (RARE) posts wider-than-expected loss but beats on sales in the second quarter of 2019.
- Zacks
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
- American City Business Journals
Health Care Digest: How California's stem cell institute may help find glaucoma cure; a stealthy biotech with $100M; and more
The future of California's stem cell research funding agency is in doubt, but its impact goes far beyond the billions of dollars it has doled out to researchers, says the Glaucoma Research Foundation.
- Zacks
Ultragenyx & Arcturus Therapeutics Expand Existing Agreement
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
- Zacks
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -54.55% and 25.40%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Do Insiders Own Lots Of Shares In Arcturus Therapeutics Ltd. (NASDAQ:ARCT)?
Every investor in Arcturus Therapeutics Ltd. (NASDAQ:ARCT) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
- Simply Wall St.
Is Arcturus Therapeutics Ltd (NASDAQ:ARCT) A Financially Sound Company?
The direct benefit for Arcturus Therapeutics Ltd (NASDAQ:ARCT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
